Project start: 1.6.2015 (tbc)
Total funding: 356.700 €
Graphene family nanoparticles (GFN) are within the group of carbon-based synthetic nanomaterials (as fullerenes, carbon nanotubes - CNT) and are currently subject of intense efforts to accelerate their toxicological characterization. Certain CNT exhibiting rigidness and a needle-like geometry show accordingly a fibre-specific carcinogenicity. Analogically GFN (i.e. graphene nanoplatelets) seem to have a specific deposition behaviour in the alveolar region due to their nano-thickness and respirability although two dimensions are at microscale. The European Commission is currently driving both innovative material science on GFN as well as the safety testing. Existing toxicity data suggest a lower toxic potential for graphenes as compared to CNT. However, the current database on GFN is scarce. This project will compare commercially available graphenes (i. pure carbon; ii. functionalised with hydroxy or carboxyl groups; iii. graphenes/graphits) using a combined in vitro and in vivo approach.
Dr. Otto Creutzenberg: email@example.com
Fraunhofer Institute for Toxicology and Experimental Medicine (Fraunhofer ITEM)
1. Fraunhofer Institute for Toxicology and Experimental Medicine (Fraunhofer ITEM),
2. BIOTOX srl,
3. University of Aveiro (UAVR)